{
  "entity_id": "B-002536",
  "folder": "Advisory-Committee-on-Chemicals-Scheduling",
  "name": "Advisory Committee on Chemicals Scheduling",
  "type": "Statutory Body",
  "jurisdiction": "Commonwealth",
  "portfolio": "Health, Disability and Ageing",
  "website": "https://www.tga.gov.au/about-tga/advisory-bodies-and-committees/advisory-committee-chemicals-scheduling-accs",
  "data_status": "partial",
  "completeness": {
    "has_strategy_brief": true,
    "has_strategy_structured": true,
    "has_vision": false,
    "has_kpi_targets": false,
    "has_kpi_results": false,
    "has_strategy_overview": true,
    "has_legislation_text": true,
    "has_legislation_structured": false,
    "has_global_initiatives_text": false,
    "has_global_initiatives_structured": false,
    "n_global_initiatives": 0,
    "has_ideas": true,
    "has_artifacts": true,
    "n_ideas": 12,
    "n_legislation": 0,
    "n_artifacts": 2,
    "n_kpi_targets": 0,
    "n_kpi_results": 0,
    "n_outcomes": 1,
    "verified_own_data": true
  },
  "strategy_profile": {
    "status": "needs_review",
    "confidence": "medium",
    "summary": "The Medical Devices Consumer Working Group (MDCWG) provides a forum for the Therapeutic Goods Administration (TGA) to work with consumer and patient groups to implement the TGA’s 2019 Action Plan for Medical Devices (Action Plan) and seek consumer perspectives on medical devices regulatory reforms.",
    "official_site_url": "https://www.tga.gov.au/about-tga/advisory-bodies-and-committees/advisory-committee-chemicals-scheduling-accs",
    "source_documents": [],
    "purpose": {
      "text": "The Medical Devices Consumer Working Group (MDCWG) provides a forum for the Therapeutic Goods Administration (TGA) to work with consumer and patient groups to implement the TGA’s 2019 Action Plan for Medical Devices (Action Plan) and seek consumer perspectives on medical devices regulatory reforms.",
      "source_url": "https://www.tga.gov.au/sites/default/files/2024-05/medical-devices-consumer-working-group-terms-of-reference.pdf",
      "source_page": 4,
      "source_deep_url": "https://www.tga.gov.au/sites/default/files/2024-05/medical-devices-consumer-working-group-terms-of-reference.pdf#page=4"
    },
    "vision": null,
    "strategic_priorities": [],
    "values": [],
    "outcomes": [
      {
        "name": "Outcome 1: Patient-centred medical device regulations",
        "description": "The MDCWG ensures that medical device regulations and the reforms are patient-centred, and transparent, supporting the Action Plan in strengthening Australia’s regulatory system, to improve health outcomes for patients who require medical devices.",
        "activities": [
          "Consider and provide advice on proposed actions to improve medical devices regulatory transparency",
          "Discuss concerns affecting consumer groups",
          "Assist the TGA with engaging with relevant stakeholders",
          "Progress activities recommended in agreed workplans"
        ],
        "source_url": "https://www.tga.gov.au/sites/default/files/2024-05/medical-devices-consumer-working-group-terms-of-reference.pdf",
        "source_page": 4,
        "source_deep_url": "https://www.tga.gov.au/sites/default/files/2024-05/medical-devices-consumer-working-group-terms-of-reference.pdf#page=4"
      }
    ],
    "performance_measures": [],
    "document_alignment_terms": {
      "must_support": [
        "The Medical Devices Consumer Working Group (MDCWG) provides a forum for the Therapeutic Goods Administration (TGA) to work with consumer and patient groups to implement the TGA’s 2"
      ],
      "watch_terms": [],
      "avoid_claiming_without_evidence": []
    },
    "review_note": "Structured strategy exists but is incomplete."
  },
  "global_initiatives": null,
  "strategy": {
    "reporting_period": "2024-25",
    "corporate_plan_period": "2025-26",
    "vision": null,
    "vision_source_page": null,
    "purposes": "The Medical Devices Consumer Working Group (MDCWG) provides a forum for the Therapeutic Goods Administration (TGA) to work with consumer and patient groups to implement the TGA’s 2019 Action Plan for Medical Devices (Action Plan) and seek consumer perspectives on medical devices regulatory reforms.",
    "purposes_source_page": 4,
    "how_we_deliver": null,
    "how_we_deliver_source_page": null,
    "government_priorities": [],
    "outcomes": [
      {
        "name": "Outcome 1: Patient-centred medical device regulations",
        "description": "The MDCWG ensures that medical device regulations and the reforms are patient-centred, and transparent, supporting the Action Plan in strengthening Australia’s regulatory system, to improve health outcomes for patients who require medical devices.",
        "key_activities": [
          "Consider and provide advice on proposed actions to improve medical devices regulatory transparency",
          "Discuss concerns affecting consumer groups",
          "Assist the TGA with engaging with relevant stakeholders",
          "Progress activities recommended in agreed workplans"
        ],
        "source_page": 4
      }
    ],
    "values": [],
    "values_framework_name": null,
    "kpi_targets_2025_26": [],
    "kpi_results_2024_25": [],
    "_source_urls": {
      "annual_report_url": "",
      "corporate_plan_url": ""
    }
  },
  "ideas": [
    {
      "entity_id": "B-002536",
      "entity_name": "Advisory Committee on Chemicals Scheduling",
      "folder_name": "Advisory-Committee-on-Chemicals-Scheduling",
      "category": "Regulation & Policy",
      "scale": "small",
      "title": "Regulatory burden scan for forms, guidance, and reporting",
      "idea": "Identify the top 10 highest-friction reporting obligations and simplify guidance, forms, or evidence requirements.",
      "quote": "TGA key performance indicators and measures: Regulator Performance Framework\n1 May 2015\nPage\nThe Regulator Performance Framework was developed to measure the performance of regulators and will apply from 1 July 2015.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Regulated entities / policy teams",
      "source": "pages/corporate-plans-index.html (https://www.tga.gov.au/about-us/corporate-plans-and-reports)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002536",
      "entity_name": "Advisory Committee on Chemicals Scheduling",
      "folder_name": "Advisory-Committee-on-Chemicals-Scheduling",
      "category": "Regulation & Policy",
      "scale": "large",
      "title": "Adaptive regulation program with live feedback loops",
      "idea": "Create an adaptive regulation model using sandboxes, industry data, risk scoring, and regular rule updates.",
      "quote": "TGA key performance indicators and measures: Regulator Performance Framework\n1 May 2015\nPage\nThe Regulator Performance Framework was developed to measure the performance of regulators and will apply from 1 July 2015.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Regulated entities / policy teams",
      "source": "pages/corporate-plans-index.html (https://www.tga.gov.au/about-us/corporate-plans-and-reports)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002536",
      "entity_name": "Advisory Committee on Chemicals Scheduling",
      "folder_name": "Advisory-Committee-on-Chemicals-Scheduling",
      "category": "Data & Performance",
      "scale": "small",
      "title": "KPI evidence register with named owners",
      "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.",
      "quote": "TGA key performance indicators and measures: Regulator Performance Framework\n1 May 2015\nPage\nThe Regulator Performance Framework was developed to measure the performance of regulators and will apply from 1 July 2015.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "pages/corporate-plans-index.html (https://www.tga.gov.au/about-us/corporate-plans-and-reports)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002536",
      "entity_name": "Advisory Committee on Chemicals Scheduling",
      "folder_name": "Advisory-Committee-on-Chemicals-Scheduling",
      "category": "Data & Performance",
      "scale": "large",
      "title": "Outcome dashboard linking budget, delivery, and public impact",
      "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.",
      "quote": "TGA key performance indicators and measures: Regulator Performance Framework\n1 May 2015\nPage\nThe Regulator Performance Framework was developed to measure the performance of regulators and will apply from 1 July 2015.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "pages/corporate-plans-index.html (https://www.tga.gov.au/about-us/corporate-plans-and-reports)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002536",
      "entity_name": "Advisory Committee on Chemicals Scheduling",
      "folder_name": "Advisory-Committee-on-Chemicals-Scheduling",
      "category": "Risk & Assurance",
      "scale": "small",
      "title": "Recommendation tracker for audits, reviews, and inquiries",
      "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.",
      "quote": "The working group continued discussions on the TGA risk assessment framework for breast implants, including how to enhance the framework’s adaptability to include a broader spectrum of topics on breast implant-related issues.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "pages/taskforces-index__09.html (https://www.tga.gov.au/about-us/committees-and-advisory-bodies/breast-implant-expert-and-consumer-working-groups)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002536",
      "entity_name": "Advisory Committee on Chemicals Scheduling",
      "folder_name": "Advisory-Committee-on-Chemicals-Scheduling",
      "category": "Risk & Assurance",
      "scale": "large",
      "title": "Integrated assurance and lessons-learned system",
      "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.",
      "quote": "The working group continued discussions on the TGA risk assessment framework for breast implants, including how to enhance the framework’s adaptability to include a broader spectrum of topics on breast implant-related issues.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "pages/taskforces-index__09.html (https://www.tga.gov.au/about-us/committees-and-advisory-bodies/breast-implant-expert-and-consumer-working-groups)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002536",
      "entity_name": "Advisory Committee on Chemicals Scheduling",
      "folder_name": "Advisory-Committee-on-Chemicals-Scheduling",
      "category": "Citizen Participation",
      "scale": "small",
      "title": "Consultation feedback summaries with response tracking",
      "idea": "Summarise consultation submissions by theme and publish what changed in response.",
      "quote": "ACM meeting statement, Meeting 55, 5 February 2026\n5 March 2026\nMeeting statements\nAdvisory Committee on Medicines meeting statement\nAll publications\nLatest consultations\nConsultation: Improvements to the regulation of sunscreens in Australia\n23 May 2026\nConsultation\nWe are seeking feedback on proposed changes to improve the regulation of therapeutic sunscreens in Australia.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / stakeholders / policy teams",
      "source": "pages/news-latest.html (https://www.tga.gov.au/news)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-002536",
      "entity_name": "Advisory Committee on Chemicals Scheduling",
      "folder_name": "Advisory-Committee-on-Chemicals-Scheduling",
      "category": "Citizen Participation",
      "scale": "large",
      "title": "Always-on policy participation platform",
      "idea": "Create a standing participation platform where citizens and stakeholders can propose, vote, and track ideas.",
      "quote": "ACM meeting statement, Meeting 55, 5 February 2026\n5 March 2026\nMeeting statements\nAdvisory Committee on Medicines meeting statement\nAll publications\nLatest consultations\nConsultation: Improvements to the regulation of sunscreens in Australia\n23 May 2026\nConsultation\nWe are seeking feedback on proposed changes to improve the regulation of therapeutic sunscreens in Australia.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / stakeholders / policy teams",
      "source": "pages/news-latest.html (https://www.tga.gov.au/news)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-002536",
      "entity_name": "Advisory Committee on Chemicals Scheduling",
      "folder_name": "Advisory-Committee-on-Chemicals-Scheduling",
      "category": "Staff Productivity",
      "scale": "small",
      "title": "Reusable briefing and summary assistant for internal documents",
      "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.",
      "quote": "Its purpose is to:\ndiscuss issues relating to the regulation of women's health products as they relate to women's health\nprovide advice to the Minister on relevant issues\nsupport other evidence-based outcomes under the National Women’s Health Strategy 2020-30.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "APS staff / executives",
      "source": "pages/taskforces-index__08.html (https://www.tga.gov.au/about-us/committees-and-advisory-bodies/womens-health-products-working-group)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Sensitive information leakage",
        "Inconsistent quality of generated drafts"
      ]
    },
    {
      "entity_id": "B-002536",
      "entity_name": "Advisory Committee on Chemicals Scheduling",
      "folder_name": "Advisory-Committee-on-Chemicals-Scheduling",
      "category": "Staff Productivity",
      "scale": "large",
      "title": "Department-wide knowledge and briefing platform",
      "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.",
      "quote": "Its purpose is to:\ndiscuss issues relating to the regulation of women's health products as they relate to women's health\nprovide advice to the Minister on relevant issues\nsupport other evidence-based outcomes under the National Women’s Health Strategy 2020-30.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "APS staff / executives",
      "source": "pages/taskforces-index__08.html (https://www.tga.gov.au/about-us/committees-and-advisory-bodies/womens-health-products-working-group)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Sensitive information leakage",
        "Inconsistent quality of generated drafts"
      ]
    },
    {
      "entity_id": "B-002536",
      "entity_name": "Advisory Committee on Chemicals Scheduling",
      "folder_name": "Advisory-Committee-on-Chemicals-Scheduling",
      "category": "Case Processing",
      "scale": "small",
      "title": "Triage queue for stuck or ageing cases",
      "idea": "Use existing case data to flag ageing, duplicate, incomplete, or high-risk cases for earlier intervention.",
      "quote": "The working group continued discussions on the TGA risk assessment framework for breast implants, including how to enhance the framework’s adaptability to include a broader spectrum of topics on breast implant-related issues.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Applicants / case officers",
      "source": "pages/taskforces-index__09.html (https://www.tga.gov.au/about-us/committees-and-advisory-bodies/breast-implant-expert-and-consumer-working-groups)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002536",
      "entity_name": "Advisory Committee on Chemicals Scheduling",
      "folder_name": "Advisory-Committee-on-Chemicals-Scheduling",
      "category": "Case Processing",
      "scale": "large",
      "title": "End-to-end case processing redesign",
      "idea": "Redesign the case pathway around risk-based triage, reusable evidence, and automated eligibility checks.",
      "quote": "The working group continued discussions on the TGA risk assessment framework for breast implants, including how to enhance the framework’s adaptability to include a broader spectrum of topics on breast implant-related issues.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Applicants / case officers",
      "source": "pages/taskforces-index__09.html (https://www.tga.gov.au/about-us/committees-and-advisory-bodies/breast-implant-expert-and-consumer-working-groups)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    }
  ],
  "legislation_administered": [],
  "artifacts": [
    {
      "category": "other-pdfs",
      "year": "2024",
      "url": "https://www.tga.gov.au/sites/default/files/2024-05/medical-devices-consumer-working-group-terms-of-reference.pdf",
      "file": "other-pdfs/medical-devices-consumer-working-group-terms-of-reference.pdf",
      "bytes": 332294,
      "link_text": "Medical Devices Consumer Working Group: Terms of Reference"
    },
    {
      "category": "other-pdfs",
      "year": "2023",
      "url": "https://www.tga.gov.au/sites/default/files/2023-05/patient-information-materials-for-medical-implants-a-fact-sheet-for-consumers.PDF",
      "file": "other-pdfs/patient-information-materials-for-medical-implants-a-fact-sheet-for-consumers.pdf",
      "bytes": 1646717,
      "link_text": "Patient information materials for medical implants: a fact sheet for consumers"
    }
  ],
  "_meta": {
    "snapshot_built_at": "2026-05-14T02:12:05+00:00",
    "strategy_brief_meta": {
      "model": "nova-micro",
      "folder": "Advisory-Committee-on-Chemicals-Scheduling",
      "annual_report": {
        "file": null,
        "url": "",
        "year": null
      },
      "corporate_plan": {
        "file": "other-pdfs\\medical-devices-consumer-working-group-terms-of-reference.txt",
        "url": "https://www.tga.gov.au/sites/default/files/2024-05/medical-devices-consumer-working-group-terms-of-reference.pdf",
        "year": null
      },
      "usage": {
        "input_tokens": 3662,
        "output_tokens": 343,
        "total_tokens": 4005,
        "model": "nova-micro"
      },
      "cost_usd": 0.00017619,
      "elapsed_seconds": 1.77,
      "generated_at": "2026-05-13T05:15:28+00:00"
    },
    "ideas_manifest": {
      "entity_id": "B-002536",
      "entity_name": "Advisory Committee on Chemicals Scheduling",
      "folder_name": "Advisory-Committee-on-Chemicals-Scheduling",
      "generated_at": "2026-05-09T23:05:35.745738+00:00",
      "idea_count": 12,
      "markdown": "ideas/Advisory-Committee-on-Chemicals-Scheduling_ideas.md",
      "jsonl": "ideas/ideas.jsonl",
      "inputs": [
        "Advisory-Committee-on-Chemicals-Scheduling_strategy-overview.md",
        "strategy-evidence.json",
        "global-intelligence/source-manifest.json"
      ]
    },
    "global_intel_meta": null
  }
}